Cardiovascular risk assessment and lipid modification

Update information

May 2023: Changes have been made to align this quality standard with the updated NICE guideline on cardiovascular disease: risk assessment and reduction, including lipid modification. Statements 1 and 7 have been updated to reflect changes to the guidance on identifying and assessing cardiovascular disease risk, and lipid modification therapy for the primary and secondary prevention of cardiovascular disease. Links, definitions, equality and diversity considerations and source guidance sections have also been updated throughout.

Minor changes since publication

December 2023: Changes have been made to the source guidance sections of this quality standard to align with the updated NICE guideline on cardiovascular disease: risk assessment and reduction, including lipid modification. Quality measures have been updated to include reference to sources of nationally collected data where available and additional process and outcome measures added to statements 4, 5 and 6. Quality statement 8 has been amended to align with underpinning recommendations that have been updated.